RankAlpha logo
Back to Rankings

AVIR

AteaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
AVIR vs peer average
42/100
AVIR vs. peer average (D vs. C)
Grade spread
A 1 · B 1 · C 2 · D 4 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

ABBV is the first available peer comparator.

Direct HCV commercial comparator rather than a same-market-cap peer: Atea identifies Mavyret as one of the major branded HCV regimens, making ABBV relevant for treatment-duration, cure-rate, tolerability, and market-positioning comparisons if AVIR's regimen succeeds [#10-K-2026-03-05].

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerABBVAbbVie
AVIR
Atea
ABBV
AbbVie
Grade
D
B
Momentum
12
51
Value
41
62
Sentiment
67
54
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Defensive
Constructive
Open Side-by-Side ComparisonCompare all

Grade position vs ABBV

AVIR / ABBV
Grade Position
Below peers
AVIR vs. peer average (D vs. C)
42/100
Momentum
12
ABBV
Value
41
ABBV
Sentiment
67
AVIR

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs AVIR
1
ABBV
ABBV
B
80/100
-2
2
GILD
GILD
C
60/100
-1
3
LRMR
Larimar Therapeutics Inc Common
D
40/100
Even
4
NAUT
Nautilus Biotechnology Inc Common
D
40/100
Even
5
RGNX
REGENXBIO Inc Common
F
20/100
+1
ABBV is the first peer returned for this comparison set.